Treatment of light chain deposition disease with bortezomib and dexamethasone

Haematologica

Volumn 94, Issue 2, 2009, Pages 300-302

  Kastritis, Efstathios ^a   Migkou, Magdalini ^a   Gavriatopoulou, Maria ^a   Zirogiannis, Panos ^b   Hadjikonstantinou, Valsamakis ^c   Dimopoulos, Meletios A ^a,d  

^a UNIVERSITY OF ATHENS   (Greece)

^b G GENNIMATAS GENERAL HOSPITAL   (Greece)

^c EVANGELISMOS HOSPITAL   (Greece)

^d ALEXANDRA HOSPITAL   (Greece)

Author keywords

Autologous transplantation; Glomerulosclerosis; Proteinuria; Renal failure

Indexed keywords

ANTIHYPERTENSIVE AGENT; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; PREDNISONE; VINCRISTINE;

ADULT; AGED; BLOOD PRESSURE; BONE MARROW BIOPSY; CONSTIPATION; DRUG DOSE REDUCTION; ECHOCARDIOGRAPHY; ELECTROPHORESIS; FEMALE; HUMAN; HYPERTENSION; KIDNEY BIOPSY; KIDNEY FUNCTION; LETTER; LIGHT CHAIN DEPOSITION DISEASE; MALE; MULTIPLE CYCLE TREATMENT; ORTHOSTATIC HYPOTENSION; PERIPHERAL NEUROPATHY; PLASMA CELL DYSCRASIA; PROTEINURIA;

AGED; BORONIC ACIDS; DEXAMETHASONE; FEMALE; HUMANS; MALE; MIDDLE AGED; PARAPROTEINEMIAS; PYRAZINES; TREATMENT OUTCOME;

EID: 59449083261     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.13548     Document Type: Letter

References (13)

1. Buxbaum J, Gallo G. Nonamyloidotic monoclonal immunoglobulin deposition disease. Light-chain, heavychain, and light- and heavy-chain deposition diseases. Hematol Oncol Clin North Am 1999;13:1235-48.
2. Pozzi C, D'Amico M, Fogazzi GB, Curioni S, Ferrario F, Pasquali S, et al. Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors. Am J Kidney Dis 2003;42:1154-63.
3. Ronco PM, Alyanakian MA, Mougenot B, Aucouturier P. Light chain deposition disease: a model of glomerulosclerosis defined at the molecular level. J Am Soc Nephrol 2001;12:1558-65.
4. Heilman RL, Velosa JA, Holley KE, Offord KP, Kyle RA. Long-term follow-up and response to chemotherapy in patients with light-chain deposition disease. Am J Kidney Dis 1992;20:34-41.
5. Lorenz EC, Gertz MA, Fervenza FC, Dispenzieri A, Lacy MQ, Hayman SR, et al. Long-term outcome of autologous stem cell transplantation in light chain deposition disease. Nephrol Dial Transplant 2008;23:2052-7.
6. Royer B, Arnulf B, Martinez F, Roy L, Flageul B, Etienne I, et al. High dose chemotherapy in light chain or light and heavy chain deposition disease. Kidney Int 2004;65:642-8.
7. Chanan-Khan AA, Kaufman JL, Mehta J, Richardson PG, Miller KC, Lonial S, et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood 2007;109:2604-6.
8. Kastritis E, Anagnostopoulos A, Roussou M, Toumanidis S, Pamboukas C, Migkou M, et al. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica 2007;92:1351-8.
9. Ludwig H, Drach J, Graf H, Lang A, Meran JG. Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma. Haematologica 2007;92:1411-4.
10. Keeling J, Herrera GA. The mesangium as a target for glomerulopathic light and heavy chains: pathogenic considerations in light and heavy chain-mediated glomerular damage. Contrib Nephrol 2007;153:116-34.
11. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, et al. NF-k B as a therapeutic target in multiple myeloma. J Biol Chem 2002;277:16639-47.
12. Wagner-Ballon O, Pisani DF, Gastinne T, Tulliez M, Chaligné R, Lacout C, et al. Proteasome inhibitor bortezomib impairs both myelofibrosis and osteosclerosis induced by high thrombopoietin levels in mice. Blood 2007;110:345-53.
13. Fineschi S, Reith W, Guerne PA, Dayer JM, Chizzolini C. Proteasome blockade exerts an antifibrotic activity by coordinately down-regulating type I collagen and tissue inhibitor of metalloproteinase-1 and up-regulating metalloproteinase-1 production in human dermal fibroblasts. Faseb J 2006;20:562-4.4.